| Literature DB >> 28911476 |
Abstract
Diabetes is a condition in which there is an elevation of blood glucose. Insulin, which is produced by the pancreas, is an important hormone needed by the body because it enables glucose to be transported into cells. Under the diabetic condition, the cells may not respond properly to insulin or the body does not produce a sufficient amount of insulin, or both. This situation will cause glucose accumulation in the blood that leads to major complications. Oral insulin therapy has been used for many years; however, coagulation in an acidic environment decreases the efficacy of insulin by neutralizing its actions. Several researchers have found that camel milk can be an adjunct to insulin therapy. It appears to be safe and effective in improving long-term glycemic control. Therefore, the aim of this study was to review in vivo studies on the effect of camel milk as a potential therapy for controlling diabetes and its complications such as high cholesterol levels, liver and kidney disease, decreased oxidative stress, and delayed wound healing.Entities:
Keywords: antihyperglycemic; antihyperlipidemic; camel milk; diabetes; oxidative stress; wound healing
Year: 2015 PMID: 28911476 PMCID: PMC9345463 DOI: 10.1016/j.jfda.2015.02.007
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Fig. 1The properties of camel milk insulin-like proteins
Antihyperglycemic effect of camel milk in vivo in animal models.
| Refs | Diabetogenic | Model of study | Dosages (daily) | Duration | Blood glucose before | Blood glucose after | Insulin | |
|---|---|---|---|---|---|---|---|---|
| Agrawal et al [ | STZ (50 mg/kg body weight by intraperitoneal administration) | Rats ( | 250 mL (raw camel milk) | 3 wk | 191.33 ± 7.46 mg/dL | 86.25 ± 12.77 mg/dL | ND | < 0.05 |
| 250 mL (raw cattle milk | 110.0 ± 9.97 mg/dL | |||||||
| Agrawal et al [ | STZ (50 mg/kg body weight by intraperitoneal administration) | Rats ( | 25 mL (raw camel milk) | 4 wk | 169.69 ± 28.73 mg/dL | 81.54 ± 11.43 mg/dL | ND | < 0.02 |
| 25 mL (pasteurized camel milk) | 135.45 ± 20.91 mg/dL | 113.08 ± 29.09 mg/dL | < 0.5 | |||||
| Sboui et al [ | Alloxan (65 mg/kg dissolved in normal saline at a concentration of 100 mg/mL) by intravenous administration) | Dogs ( | 500 mL (raw camel milk) | 5 wk | 10.88 ± 0.55 mmol/L | 5.77 ± 0.44 mmol/L | ND | < 0.05 |
| El-Said et al [ | Alloxan (90 mg/kg dissolved in 5 mL of normal saline) via the ear vein | Rabbits ( | 7 mL/kg of raw camel milk | 4 wk | 528.4 ± 28.2 mg/dL | 116.6 ± 11.9 mg/dL | < 0.05 | |
| Biosynthetic human insulin (HuNil) 1.5 IU/kg | 205.7 ± 15 mg/dL | |||||||
| Al-Numair et al [ | STZ (40 mg/kg body weight by intraperitoneal administration) | Rats ( | 250 mL (raw camel milk) | 45 d | 292.38 ± 19.20 mg/dL | 141.57 ± 12.82 mg/dL | < 0.05 | |
| Hamad et al [ | STZ (60 mg/kg body weight by intraperitoneal | Rats ( | 20 mL camel milk +95 g basal diet | 6 wk | 146 ± 9.8 mg/dL | 101 ± 9.7 mg/dL | ND | < 0.05 |
| 20 mL cow milk+ 95 g basal diet | 200 ± 11.1 mg/dL | 176 ± 8.9 mg/dL | ||||||
| 20 mL buffalo milk+ 95 g basal diet | 197 ± 10.1 mg/dL | 177 ± 9.0 mg/dL | ||||||
| Khan et al [ | STZ (55 mg/kg body weight by intraperitoneal administration) | Rats ( | 400 mL of raw camel milk | 4 wk | 520.46 ± 8.90 mg/dL | 235.61 ± 7.10 mg/dL | ND | < 0.05 |
| Badr [ | STZ (60 mg/kg body weight by intraperitoneal administration) | Mouse ( | Undenatured camel milk whey protein (100 mg/kg of body weight) | 2 wk | 411 ± 37 mg/dL | 261 ± 25.5 mg/dL | <0.05 |
= The level of significance at p value when compared with data before treatment.
↑ = increase; ND = not detected; STZ = streptozotocin.
Antihyperglycemic effect of camel milk in type 1 diabetic patients.
| Refs | Dosages (daily) | No. of samples | Duration | Blood glucose before (mg/dL) | Blood glucose after (mg/dL) | Dose of insulin (units/d) |
|
|---|---|---|---|---|---|---|---|
| Agrawal et al [ | 500 mL raw camel milk | 3 mo | 115.16 ± 7.17 | 100 ± 16.2 | |||
| Agrawal et al [ | 500 mL raw camel milk | 52 wk | 119 ± 19 | 95.42 ± 15.70 | |||
| Agrawal et al [ | 500 mL of raw camel milk | 12 mo | 115.16 ± 14.50 | 100.20 ± 17.40 | |||
| Agrawal et al [ | 500 mL of raw camel milk | 6 mo | 128.7 ± 1.17 | 125.46 ± 1.24 | |||
| Mohamad et al [ | 500 mL raw camel milk | 4 mo | 227.2 ± 17.7 | 98.9 ± 16.2 | |||
| El-Sayed et al [ | 500 mL raw camel milk | 3 mo | 199.46 ± 4 | 155.13 ± 3.5 | |||
| Insulin treatment | 195.6 ± 2.01 | 173.4 ± 1.66 | |||||
| 500 mL camel milk + insulin | 205.3 ± 2.16 | 147.26 ±1.89 |
= The level of significance at p value when compared with data before treatment.
↓ = decrease.
Antihyperlipidemic effect of camel milk in in vivo animal models.
| Refs | Dosages (daily) & duration | No. of sample | Duration | TG | TC | PLs | HDL-C | LDL-C | VLDL-C | FFA | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| El-Said et al [ | 7 mL/kg of raw camel milk | Rabbits ( | 4 wk | ↓ From 603.4 ± 9.6 to 524.8 ± 14.2 mg/dL | ↑ From 274.2 ± 6.6 to 295.9 ± 7.9 mg/dL | ↑ From 214.5± 41.3 to 364.2 ± 38.4 mg/dL | ↓ From 52.1 ± 1.0 to 36.4 ± 3.8 mg/dL | ↑ From 119.7 ± 0.4 to 168.8 ± 0.4 mg/dL | ND | ND | < 0.05 |
| Sboui et al, [ | 500 mL of raw camel milk | Dogs ( | 5 wk | From 1.03 ± 0.17 to 1.03 ± 0.3 mmol/L | ↓From 6.17 ± 0.5 to 4.35 ± 0.61 mmol/L | ND | ND | ND | ND | ND | < 0.05 |
| 500 mL of raw cow milk | ↑ From 1.03 ± 0.17 to 1.14 ± 0.33 mmol/L | ↑ From 5.99 ± 0.58 to 7.13 ± 1.25 mmol/L | |||||||||
| Al-Numair [ | 250 mL raw camel milk | Rats ( | 45 d | ↓ From 157.19 ± 14.14 to 116.40 ± 6.34 mg/dL | ↓ From 169.81 ± 10.24 to 98.28 ± 6.36 mg/dL | ↓ From 160.99 ± 11.62 to 103.66 ± 9.33 mg/dL | ↑ From 34.60 ± 2.57 to 39.03 ± 2.19 mg/dL | ↓ From 32.23 ± 2.82 to 24.08 ± 1.26 mg/dL | ↓ From 105.97 ± 7.81 to 38.16 ± 3.25 mg/dL | ↓ From 140.48 ± 10.46 to 80.69 ± 5.63 mg/dL | < 0.05 |
| Khan et al [ | 400 mL of raw camel milk | Rats ( | 4 wk | ↓ From 167.43 ± 5.8 to 109.23 ± 6.3 mg/dL | ↓ From 298.31 ± 12.4 to 196.27 ± 11.9 mg/dL | ND | ↓ From 58.43 ± 6.8 to 52.37 ± 5.6 mg/dL | ↓ From 191.31 ± 8.4 to 128.34 ± 5.9 mg/dL | ND | ND | < 0.05 |
| Ali et al [ | Fermented camel milk (Gariss) diet formula | Rats ( | 6 wk | ↓ From 144.27 ± 4.47 to 68.25 ± 3.30 mg/100 mL | ↓From 135.79 ± 8.74 to 87.93 ± 4.00 mg/100 mL | ND | ↑ From 11.66 ± 1.29 to 28.78 ± 1.07 mg/100 mL | ND | ND | ND | < 0.05 |
= The level of significance at p value when compared with data before treatment.
FFA = free fatty acid; HDL-C = high-density lipoprotein-C; LDL-C = low-density lipoprotein-C; ND = not detected; PLs = phospholipids; TC = total cholesterol; TG = triacylglycerols; VLDL-C = very-low-density lipoprotein-C.
Antihyperlipidemic effect of camel milk in type 1 diabetic patients.
| Refs | Dosages (daily) | No. of samples | Duration | TG (mg/dL) | TC (mg/dL) | HDL-C (mg/dL) | LDL-C (mg/dL) | VLDL-C (mg/dL) |
|
|---|---|---|---|---|---|---|---|---|---|
| Agrawal et al [ | 500 mL raw camel milk | 3 mo. | ↓ From 66.91 ± 25.6 to 60.16 ± 25.16 | ↓ From 164.58 ± 20.59 to 158.33 ± 21.55 | ↑ From 62.58 ± 13.91 to 66.66 ± 11.29 | ↓ From 92 ± 11.62 to 79.16 ± 17.75 | ↓From 13.5 ± 5 to 12.08 ± 5.08 | <0.040 | |
| Agrawal et al [ | 500 mL of raw camel milk | 6 mo. | ↓ From 92.76 ± 0.18 to 31.5 ± 0.17 | ↓ From 77.22 ± 0.03 to 76.32 ± 0.04 | ↓ From 26.82 ± 0.02 to 26.28 ± 0.03 | ↓ From 65.18 ± 0.14 to 45.54 ± 0.10 | ↓ From 6.84 ± 0.02 to 6.3 ± 0.02 | < 0.001 | |
| Mohamad et al [ | 500 mL raw camel milk | 4 mo. | ↓ From 170.41 ± 21.68 to 106.91 ± 25.60 | ↓ From 265.33 ± 9.09 to 200.08 ± 11.04 | ↓ From 53.00 ± 12.57 to 52.66 ± 10.54 | ↓ From 102.83 ± 9.6 to 87.08 ± 27.86 | ↓ From 14.41 ± 4.71 to 13.0 ± 5.44 | < 0.05 | |
| El-Sayed et al [ | 500 mL raw camel milk | 3 mo. | ↓ From 184 ± 2.1 to 133.6 ± 4.2 | ↓ From 251.8 ± 9.3 to 209.2 ± 3.2 | ↑ From 44.3 ± 2.0 to 49 ± 1.5 | ↓ From 110 ± 2.9 to 92.4 ± 2.6 | ND | ||
| Insulin treatment | ↓ From 193.1 ± 1.7 to 175.7 ± 3.0 | ↓ From 271.8 ± 3.35 to 248.6 ± 3.7 | ↑ From 43.1 ± 1.53 to 43.7 ± 1.26 | ↓ From 109.9 ± 2.45 to 102.6 ± 1.51 | < 0.001 | ||||
| 500 mL camel milk + insulin | ↓ From 182.8 ± 2.15 to 100.8 ± 2.15 | ↓ From 283.6 ± 2.56 to 153.3 ± 1.69 | ↑ From 41 ± 1.89 to 48.9 ± 1.22 ( | ↓ From 103.5 ± 2.91 to 70.6 ± 3.32 | < 0.01 |
= The level of significance at p value when compared with data before treatment.
HDL-C = high-density lipoprotein-C; LDL-C = low-density lipoprotein-C; ND = not detected; PLs = phospholipids; TC = total cholesterol; TG = triacylglycerols; VLDL-C = very low density lipoprotein-C.